Kineta, Inc. (KANT) - Net Assets
Based on the latest financial reports, Kineta, Inc. (KANT) has net assets worth $-7.98 Million USD as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.40 Million) and total liabilities ($9.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-7.98 Million |
| % of Total Assets | -570.34% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Kineta, Inc. - Net Assets Trend (2020–2023)
This chart illustrates how Kineta, Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kineta, Inc. (2020–2023)
The table below shows the annual net assets of Kineta, Inc. from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $3.06 Million | -33.06% |
| 2022-12-31 | $4.57 Million | +138.25% |
| 2021-12-31 | $-11.95 Million | +44.54% |
| 2020-12-31 | $-21.55 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kineta, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8932400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $168.68 Million | 5836.64% |
| Total Equity | $2.89 Million | 100.00% |
Kineta, Inc. Competitors by Market Cap
The table below lists competitors of Kineta, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Agereh Technologies Inc
V:AUTO
|
$4.14 Million |
|
Vision Marine Technologies Inc
NASDAQ:VMAR
|
$4.14 Million |
|
Sultan Resources Ltd
AU:SLZ
|
$4.14 Million |
|
QMC Quantum Minerals Corp
V:QMC
|
$4.14 Million |
|
Emergent Metals Corp
V:EMR
|
$4.12 Million |
|
Kuniko Ltd
AU:KNI
|
$4.12 Million |
|
1844 Resources Inc
V:EFF
|
$4.11 Million |
|
Abits Group Inc.
NASDAQ:ABTS
|
$4.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kineta, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 4,424,000 to 2,890,000, a change of -1,534,000 (-34.7%).
- Net loss of 14,099,000 reduced equity.
- New share issuances of 8,561,000 increased equity.
- Other factors increased equity by 4,004,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.10 Million | -487.85% |
| Share Issuances | $8.56 Million | +296.23% |
| Other Changes | $4.00 Million | +138.55% |
| Total Change | $- | -34.67% |
Book Value vs Market Value Analysis
This analysis compares Kineta, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.21x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.63x to 1.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $0.53 | $0.34 | x |
| 2023-12-31 | $0.28 | $0.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kineta, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -487.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -259.08%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 3.56x
- Recent ROE (-487.85%) is below the historical average (-480.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -76.77% | 0.73x | 0.00x | $-5.88 Million |
| 2021 | 0.00% | -129.99% | 0.68x | 0.00x | $-10.60 Million |
| 2022 | -1433.27% | -6091.07% | 0.06x | 3.94x | $-63.85 Million |
| 2023 | -487.85% | -259.08% | 0.53x | 3.56x | $-14.39 Million |
Industry Comparison
This section compares Kineta, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $162,630,955
- Average return on equity (ROE) among peers: -384.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kineta, Inc. (KANT) | $-7.98 Million | 0.00% | N/A | $4.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $113.87 Million |
| Abcellera Biologics Inc (ABCL) | $1.03 Billion | -0.22% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.61 Million | 0.00% | 0.00x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $186.31 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $366.11 Million | -27.58% | 0.16x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $18.37 Million | -14.06% | 0.35x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $290.29K | -1602.16% | 3.15x | $33.84 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.53 Billion |
About Kineta, Inc.
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combinati… Read more